时间标签：数据日期 2026-10-31 · 生成时间 2026-11-01 05:30（Asia/Shanghai）｜ 检索窗口 PubMed edat 2026/10/28–2026/10/31 ｜ 情报发生日期 2026-10-31
研究问题
However, their eligibility restrictions, safety concerns associated to amyloid‐related imaging abnormalities, and modest benefits underscore the need for complementary strategies beyond amyloid clearance.；Given their mechanisms – dulaglutide enhancing neurotrophic/metabolic signaling and buntanetap reducing pathogenic proteins – we hypothesized combined treatment would produce additive or synergistic effects.；We evaluated behavioral, electrophysiological, and biochemical outcomes to determine whether dual targeting of neurotrophic signaling and toxic protein burden provides greater benefit than monotherapy.
方法
The colony was established from APP mice provided by Karen Hsiao‐Ashe and PS1 mice provided by Karen Duff.；Aβ peptides were quantified by Meso Scale Discovery assay.；Hippocampal protein extracts were analyzed by Western blot.
核心结论
APP/PS1 and wild‐type (WT) littermates began i.p. buntanetap or dulaglutide treatment at 10 to 12 weeks of age, coinciding with the initial appearance of amyloid plaques.；Administration of the highest doses – buntanetap at 10 mg/kg or dulaglutide at 0.6 mg/kg – restored APP/PS1 performance to WT levels (Figure and Table ).；Titrating downward revealed a progressive loss of efficacy: Intermediate or low doses produced either no improvement or only partial benefit, as with buntanetap at 1 mg/kg and dulaglutide at 0.3 or 0.1 mg/kg (Figure and Table ). ‖ 结论：Our results provide a compelling preclinical example of this: Two agents with individually modest or partial effects, combined at low doses, achieve full restoration of synaptic and cognitive function.
局限
None of the treatments altered sensory, motor, motivational, or shock‐perception abilities, confirming genuine recovery of hippocampal function rather than non‐specific confounds.；A limitation of this study concerns the scope of our biochemical and histological analyses.；A further limitation is the absence of blood‐based or imaging biomarker measures.
对本项目的价值
★☆☆☆☆ 脑老化是最大未满足需求，也是终点最难量化的领域；biomarker 与认知读数选择最敏感。
全文来源
PMC JATS 全文（正文 26,556 字符，已过标题/DOI 逐字归属校验）
原文题录
- 英文标题：Combined administration of buntanetap and dulaglutide counteracts synaptic dysfunction and memory loss in an Alzheimer's disease mouse model.
- 期刊与标识：Alzheimers Dement (N Y) · PMID 42959452 · DOI 10.1002/trc2.70336
B 级证据分级：B 级（同行评议临床前研究，主要为动物模型）
本文核心结论来自动物模型或体外细胞学，属临床前证据，不能外推至人体。「延长健康寿命」「改善功能」等表述在小鼠中的意义，与人类临床结局之间仍有距离。
关于本文的文献来源：本站依据 IMA 知识库「五刊监控·深度文献卡片」撰写，依据已获取的期刊全文（方法、样本量与结论已回到原文核对）；未能获取全文的同批条目另行标注「摘要级」，全程未做任何数值推算补全。